2027-LB: Dermal Sensing for a Shorter Time Lag

• Published in: Diabetes (New York, N.Y.) Vol. 74; no. Supplement_1; p. 1
• Main Authors: AHMAD, KHADIJE, RULE, PETER, BANEZ, BRIANNA, HALE, DANIEL, VAN ANTWERP, BILL
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 20.06.2025
• Subjects: Chemoreception; Diabetes mellitus; Glucose; Hyperglycemia; Hypoglycemia; Insulin; Pediatrics; Sensors; Skin
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db25-2027-LB

Introduction and Objective: Current CGMs sensing glucose in the deep subcutaneous tissue have a significant time lag (t). That could result in severe hypo/hyperglycemia and lower TIR. Dermal sensing can greatly reduce time lag. Methods: In a clinical study conducted at two US-based clinical centers, subjects with type-I DM wore a novel dermal CGM + Abbott Libre 3 or Dexcom G7, all were compared to a YSI-glucose analyzer. Kinetics were modeled using the 2-compartment model and compared to commercial sensors. Commercial CGMs had varying t ranging from -6 min to +10 min. Figure 1 shows data from a visit with a Libre t of 8 min compared to dermal sensing of 0 min. Results: Data from 55 subjects showed fast kinetics. MARD was 10.4% and 94+% of the Laxmi sensors had a t of 0-2 mins. This reduction in t by a factor of 5-10 has profound implications for over/under shooting of insulin administration, in both self-administered and in a PID model of Automated Insulin Delivery. Using a well-accepted model (UVA type-I diabetes simulator), we observed 8% improvement of TIR in pediatrics with sensors of t<2 min. In the same study, analysis of accuracy over various rates of change showed statistical significance in favor of dermal sensing. Conclusion: Dermal sensing has a time lag close to 0. Individuals with DM can have lower glucose targets with a system that eliminates fear of hypoglycemia, resulting in higher TIR and better control of DM.